128 related articles for article (PubMed ID: 38837219)
1. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
Öztaş S; Er DK; Dündar D; Keçeli SA
Acta Microbiol Immunol Hung; 2024 Jun; ():. PubMed ID: 38837219
[TBL] [Abstract][Full Text] [Related]
2. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
[TBL] [Abstract][Full Text] [Related]
3. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant
Han R; Shi Q; Wu S; Yin D; Peng M; Dong D; Zheng Y; Guo Y; Zhang R; Hu F;
Front Cell Infect Microbiol; 2020; 10():314. PubMed ID: 32719751
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
[TBL] [Abstract][Full Text] [Related]
5. Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.
Shen S; Tang C; Ding L; Han R; Yin D; Yang W; Guo Y; Hu F
mSphere; 2022 Dec; 7(6):e0048722. PubMed ID: 36374086
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia.
Zornic S; Petrovic I; Lukovic B
Acta Microbiol Immunol Hung; 2023 Sep; 70(3):187-192. PubMed ID: 37535440
[TBL] [Abstract][Full Text] [Related]
7. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
[TBL] [Abstract][Full Text] [Related]
8. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
9. High proportion of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae among extended-spectrum β-lactamase-producers in Nigerian hospitals.
Olalekan A; Onwugamba F; Iwalokun B; Mellmann A; Becker K; Schaumburg F
J Glob Antimicrob Resist; 2020 Jun; 21():8-12. PubMed ID: 31525542
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
12. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.
Wei J; Zou C; Wang D; Huang A; Niu S
J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260
[TBL] [Abstract][Full Text] [Related]
13. Isolation of Hv-CRKP with co-production of three carbapenemases (
Li P; Luo WY; Xiang TX; Peng TX; Luo S; He ZY; Liao W; Wei DD; Liu P; Wan LG; Zhang W; Liu Y
Front Microbiol; 2023; 14():1182870. PubMed ID: 37293218
[TBL] [Abstract][Full Text] [Related]
14. KPC-2 allelic variants in
Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
16. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant Klebsiella pneumoniae outbreak with monoclonal spread: Evaluation of resistance genes and ceftazidime-avibactam susceptibility.
Arıcı N; Tanrıverdi ES; Çalık Ş; Kansak N; Adaleti R; Otlu B; Aksaray S
Indian J Med Microbiol; 2023; 46():100431. PubMed ID: 37945124
[TBL] [Abstract][Full Text] [Related]
18. Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates.
Tamma PD; Bergman Y; Jacobs EB; Lee JH; Lewis S; Cosgrove SE; Simner PJ;
Infect Control Hosp Epidemiol; 2023 May; 44(5):762-767. PubMed ID: 35822340
[TBL] [Abstract][Full Text] [Related]
19. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
20. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
